Skip to main content
. 2012 Aug 15;2012(8):CD007072. doi: 10.1002/14651858.CD007072.pub2
Study ID Data collection Serious Adverse Events (SAEs)** Other adverse events
Placebo Intervention Placebo Intervention
Cornuz 2008 Specific safety check‐up one week after each injection (0‐4 months), self‐assessment diaries of local reactions Overall: 3 SAEs. None attributable to treatment. Overall: 6 SAEs.
Flu‐like symptoms associated with chest pain (1)		 Flu‐like symptoms (14/112);
Pyrexia (9);
Headache (30);
Nasopharyngitis (29);
Myalgia (6);
Injection site discomfort (2)		 Flu‐like symptoms (159/229);
Pyrexia (96);
Headache (92);
Nasopharyngitis (73);
Myalgia (31);
Injection site discomfort (45)
Hatsukami 2011 Subjects instructed to record reactogenicity events for 7 days after each injection (followed up until resolution or study completion); non‐serious treatment‐emergent AEs were recorded for 4 weeks after last injection; SAEs recorded up to 52 weeks Overall: 10 SAEs in 5 subjects.
Herpes zoster (1)		 Overall: 8 SAEs in 7 subjects.
Anaphylaxis (1)
Herpes zoster (4)		 Pyrexia (10/100);
Headache (61);
Nasopharyngitis (14);
Myalgia (86);
Injection site discomfort (49)		 Pyrexia (21/201);
Headache (138);
Nasopharyngitis (18);
Myalgia (171);
Injection site discomfort (122)